Cognition Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cognition Therapeutics's earnings have been declining at an average annual rate of -28.1%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually.
Key information
-28.1%
Earnings growth rate
85.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -105.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Apr 18Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Nov 30
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
Aug 15Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
Mar 17Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Sep 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Aug 12Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
Aug 05We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Mar 19Revenue & Expenses BreakdownBeta
How Cognition Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -26 | 14 | 37 |
| 30 Sep 23 | 0 | -23 | 13 | 32 |
| 30 Jun 23 | 0 | -23 | 14 | 29 |
| 31 Mar 23 | 0 | -24 | 14 | 29 |
| 31 Dec 22 | 0 | -21 | 13 | 30 |
| 30 Sep 22 | 0 | -24 | 17 | 29 |
| 30 Jun 22 | 0 | -22 | 14 | 25 |
| 31 Mar 22 | 0 | -19 | 12 | 21 |
| 31 Dec 21 | 0 | -16 | 10 | 19 |
| 30 Sep 21 | 0 | -12 | 5 | 16 |
| 30 Jun 21 | 0 | -10 | 4 | 16 |
| 31 Mar 21 | 0 | -9 | 4 | 14 |
| 31 Dec 20 | 0 | -12 | 5 | 13 |
Quality Earnings: CGTX is currently unprofitable.
Growing Profit Margin: CGTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CGTX is unprofitable, and losses have increased over the past 5 years at a rate of 28.1% per year.
Accelerating Growth: Unable to compare CGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CGTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: CGTX has a negative Return on Equity (-105.37%), as it is currently unprofitable.